IP10 levels refine severity prognostication in COVID-19 and implicate causes of clinical deterioration: lessons for pandemic preparedness
Share:
More from IMU Biosciences
Related
IMU Biosciences Appoints Dr. Carlos Paya as Non-Executive Director, Strengthening its Board of Directors
IMU Biosciences announces formation of Scientific Advisory Board
IMU Biosciences joins ground-breaking UK research consortium investigating patient response to cancer immunotherapies
IMU Biosciences Appoints Dr. Carlos Paya as Non-Executive Director, Strengthening its Board of Directors
IMU Biosciences announces formation of Scientific Advisory Board
IMU Biosciences joins ground-breaking UK research consortium investigating patient response to cancer immunotherapies